Blog Viewer

Intravenous Immunomodulatory Nanoparticle Treatment for Traumatic Brain Injury

By Currents Editor posted 02-03-2020 12:22

  

Annals of Neurology (01/10/20)  doi.org/10.1002/ana.25675
Sharma, Sripadh; Ifergan, Igal; Kurz, Jonathan E.; et al.

Immunomodulatory nanoparticles (IMPs) – which ablate a particular subset of hematogenous monocytes – are a strong therapeutic candidate for traumatic brain injury (TBI), new research shows. Researchers from the Northwestern University Feinberg School of Medicine in Chicago administered an intravenous infusion of IMPs containing 500 nm carboxylated‐poly(lactic‐co‐glycolic) acid into wild‐type C57BL/6 mice following controlled cortical impact and closed head injury. In both models of experimental TBI, the infusion resulted in preservation of tissue and neurological function. Additionally, following acute treatment, fewer immune cells infiltrated into the brain, the inflammatory status of the infiltrating cells was mitigated, and there was greater electrophysiologic visual function, improved long-term motor behavior, fewer edemas, and lower lesion volumes. The results indicate that IMPs “are a clinically translatable acute intervention for TBI with a well‐defined mechanism of action and beneficial anatomic and physiologic preservation and recovery,” according to the researchers.

#LiteratureWatch

FURTHER READING
Stefanie P. Cappucci, MD Neurology Resident Beth Israel Deaconess Medical Center Corey R. Fehnel, MD, MPH Assistant Professor of Neurology Beth Israel Deaconess Medical Center Harvard Medical School Section Editor: Michael Reznik, MD Assistant Professor ...
Stroke   (04/29/20) doi: 10.1161/STROKEAHA.120.03010 Nguyen, Thanh N.; Abdalkader, Mohamad; Jovin, Tudor G.; et al. https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.120.030100   The Society of Vascular and Interventional Neurology (SVIN) has released a guidance statement on acute ischemic ...
By Mary Presciutti, NP, CCRN, CNRN, Mount Sinai Hospital, Department of Neurosurgery Weeks before deployment, my fellow advanced care providers (APP) and I were told that our New York City hospital was in the process of rearranging healthcare personnel to meet the impending surge of patients with ...